Close Menu

NEW YORK (GenomeWeb) – iCubate announced yesterday that it has received CE mark for its first clinical assay, the iC-GPC assay and its platform, the iC-System, used for the rapid diagnosis of pathogenic bacteria associated with bloodstream infection. The CE mark provides an entry for iCubate to begin market integration into the European Union.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.